-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Theravance Biopharma, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate for Q1 2024.
- Theravance Biopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$513K.
- Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $3.21M.
- Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2017 was $0.000.
- Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2016 was $0.000.
Deferred Income Tax Expense (Benefit), Quarterly (USD)